April 2016 in “Journal of Investigative Dermatology” MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.
4 citations
,
December 2024 in “Clinical Cosmetic and Investigational Dermatology” Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.
July 2025 in “Scientific Reports” Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.
1 citations
,
January 2010 in “Endocrine abstracts”
14 citations
,
December 1998 in “The Journal of Clinical Endocrinology and Metabolism” MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.
8 citations
,
April 2006 in “Acta dermato-venereologica” Dovobet ointment used overnight effectively reduces scalp psoriasis severity and itch.
July 2026 in “British journal of surgery” Inappropriate continuation of certain medications after surgery can be risky, highlighting the need for better guidance and communication.
156 citations
,
August 2014 in “Cochrane library” Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
59 citations
,
October 1976 in “Acta Neurologica Scandinavica” Sodium valproate reduced seizures in many patients with resistant epilepsy.
14 citations
,
June 1982 in “Archives of Dermatology” A man had bad reactions to a hair loss treatment called DNCB.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
1 citations
,
January 2013 Bimatoprost treats glaucoma and promotes hair growth, with potential for more medical uses.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
14 citations
,
June 2009 in “Journal of veterinary internal medicine” High doses of albendazole can be deadly for alpacas.
January 2025 in “Drug repurposing” New drug uses show promise but need more research.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib was effective in treating both early and late onset alopecia areata.
July 2023 in “International Journal of Molecular Sciences” Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.
October 2011 in “The American Journal of Gastroenterology” Methadone may worsen liver fibrosis in males with HCV.
2 citations
,
January 2017 in “Düşünen Adam” Agomelatine might help stop hair loss caused by valproate.
1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
8 citations
,
June 2020 in “The Journal of Clinical Endocrinology and Metabolism” Taking 5α-reductase inhibitors with prednisolone can worsen its negative effects on metabolism.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
Sodium valproate improved epilepsy control in most children but often caused weight gain and other mild side effects.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
March 2022 in “Journal of The American Academy of Dermatology”
14 citations
,
August 2021 in “Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy” Metformin, a diabetes drug, may help prevent and treat various cancers, but more research is needed.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
November 2005 in “PubMed”